Biocapital: The Constitution of Postgenomic LifeDuke University Press, 2006 M04 24 - 343 páginas Biocapital is a major theoretical contribution to science studies and political economy. Grounding his analysis in a multi-sited ethnography of genomic research and drug development marketplaces in the United States and India, Kaushik Sunder Rajan argues that contemporary biotechnologies such as genomics can only be understood in relation to the economic markets within which they emerge. Sunder Rajan conducted fieldwork in biotechnology labs and in small start-up companies in the United States (mostly in the San Francisco Bay area) and India (mainly in New Delhi, Hyderabad, and Bombay) over a five-year period spanning 1999 to 2004. He draws on his research with scientists, entrepreneurs, venture capitalists, and policymakers to compare drug development in the two countries, examining the practices and goals of research, the financing mechanisms, the relevant government regulations, and the hype and marketing surrounding promising new technologies. In the process, he illuminates the global flow of ideas, information, capital, and people connected to biotech initiatives. Sunder Rajan’s ethnography informs his theoretically sophisticated inquiry into how the contemporary world is shaped by the marriage of biotechnology and market forces, by what he calls technoscientific capitalism. Bringing Marxian theories of value into conversation with Foucaultian notions of biopolitics, he traces how the life sciences came to be significant producers of both economic and epistemic value in the late twentieth century and early twenty-first. |
Contenido
Capitalisms and Biotechnologies | 1 |
Contradictions in Market Logic in American and Indian Genome Enterprises | 39 |
Global and Local Political Ecologies of Biocapital | 77 |
The Conjuration of Promissory Biocapitalist Futures | 107 |
Genomic Facts and Personalized Medicine or Life Is a Business Plan | 138 |
Underlying Belief Structures of Biocapital | 182 |
The Story of an Elearning Company | 234 |
Surplus and Symptom | 277 |
NOTES | 289 |
REFERENCES | 315 |
327 | |
Otras ediciones - Ver todas
Términos y frases comunes
actors American analysis Andhra Pradesh argue articulation big pharmaceutical biocapital Biocon bioinformatics biological biopolitical biotech biotech companies biotechnology Brahmachari Celera Celera Genomics chapter clinical trials commodity constitute context corporate course CSIR culture discourse disease DNA chip DNA sequence dot.com drug development economic emergent entrepreneurs epistemic ethical ethnographic exchange fetishism forms free market GeneEd GeneEd's Genentech genetic genome companies global human genome Human Genome Project hype ideology Incyte India Indian innovation instance institutional intellectual property investment investors labor market logic Marx material Maulik mutations Naidu particular Patel patent personalized medicine pharmaceutical companies pharmacogenomics political economy population potential production promissory question regimes relationship Rep-X risk salvationary scientific fact scientists Scott Silicon Valley specific start-up story strategic structure surplus value technoscience technoscientific terrain tion United University Press venture capital venture capitalists venture science vision words
Referencias a este libro
The Logic of Care: Health and the Problem of Patient Choice Annemarie Mol Sin vista previa disponible - 2008 |